Dhodh Inhibitors and Their Use as Antiviral Agents

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent discloses a new class of anthranilic acid derivatives that act as potent inhibitors of the host enzyme dihydroorotate dehydrogenase (DHODH). By inhibiting DHODH, these compounds interrupt the de novo synthesis of pyrimidine nucleotides critical for the replication of RNA viruses. As a result, the compounds serve as broad-spectrum antiviral agents, demonstrating high efficacy against a wide range of RNA viruses. The patent also details the chemical structures, pharmaceutical compositions, and demonstrates promising in vitro antiviral activities, as well as favorable safety and pharmacokinetic properties.

Use CasesContent extracted from patent full text and abstract with AI.

• Treatment of infections by a broad range of RNA viruses (e.g., SARS-CoV-2, dengue virus, Zika virus, Ebola, Lassa fever, hepatitis C, and others).
• Development of broad-spectrum antiviral therapeutics, including oral and injectable pharmaceuticals.
• Countermeasure development for emerging or pandemic viral threats.
• Potential use in immunosuppressive therapy and the treatment of autoimmune diseases (like rheumatoid arthritis, multiple sclerosis).
• Application in organ transplantation for immunosuppression.
• Possible uses in oncology (cancer treatment) and anti-parasite therapy (e.g., malaria, crop protection).

BenefitsContent extracted from patent full text and abstract with AI.

• Broad-spectrum antiviral activity against diverse RNA viruses, allowing for a single therapy to target multiple pathogens.
• Higher barrier to resistance development compared to direct-acting antivirals, as DHODH is a host enzyme rather than a viral protein.
• Therapeutic potential for newly emerging and drug-resistant RNA viruses without available specific treatments.
• Low cytotoxicity and improved safety profiles compared to previous DHODH inhibitors (such as teriflunomide or brequinar).
• Compounds exhibit suitable pharmacokinetic and ADME properties for drug development.
• Oral and injectable formulations possible, enhancing flexibility in clinical applications.
• Synthesis of the compounds is straightforward and efficient, allowing for scalability in manufacturing.
• Potential utility in various therapeutic areas beyond virology, including autoimmune diseases, transplantation, oncology, and parasitology.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention relates to a compound, or a dimer or a pharmaceutically acceptable salt or solvate of said compound or dimer, for use in a method for the treatment of a disease, disorder or condition caused by an RNA virus, said compound having the general structure shown in Formula (I).